Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 3/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | RAB9A | P51151 | 2/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.71 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.70 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.67 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.62 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.61 |
| ▸ | RHOC | P08134 | 1/20 | 0.60 |
| ▸ | RHOA | P61586 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28268751 | 0.90 | RAB9A (0.74) | MAPTMEN1KMT2ARAB9AHTT | |
| SCHEMBL28007500 | 0.88 | RAB9A (0.70) | MAPTMEN1KMT2ARAB9AHTT | |
| SCHEMBL4656855 | 0.87 | MAPT (0.78) | MAPTMEN1KMT2ARAB9AHTT | |
| SCHEMBL4286068 | 0.87 | MAPT (0.94) | MAPTMEN1KMT2ARAB9AHTT | |
| SCHEMBL31355711 | 0.87 | CES2 (0.65) | MAPTMEN1KMT2ARAB9AHTT | |
| SCHEMBL40351 | 0.87 | CES2 (0.65) | MAPTMEN1KMT2ARAB9AHTT | |
| SCHEMBL15848265 | 0.87 | ALDH1A1 (0.59) | MAPTMEN1KMT2ARAB9AHTT | |
| Ethane SCHEMBL27386119 | 0.85 | CES2 (0.62) | MAPTMEN1KMT2ARAB9AHTT | |
| SCHEMBL2494871 | 0.85 | KCNK3 (0.81) | MAPTMEN1KMT2ARAB9AHTT | |
| SCHEMBL15094033 | 0.85 | MAPT (0.78) | MAPTMEN1KMT2ARAB9AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10604493-B2 | Compositions, methods of use, and methods of treatment | UNIVERSITY OF SOUTH FLORIDA (US) | 2020-03-31 | — | — | US | disclosed |
| US-20170088524-A1 | Compositions, Methods of Use, And Methods of Treatment | UNIVERSITY OF SOUTH FLORIDA | 2017-03-30 | — | — | US | disclosed |
| US-9556131-B2 | Compositions, methods of use, and methods of treatment | UNIVERSITY OF SOUTH FLORIDA (US) | 2017-01-31 | — | — | US | disclosed |
| US-9403823-B2 | Protein kinase inhibitors | ORIBASE PHARMA (FR) | 2016-08-02 | — | — | US | disclosed |
| US-20160009709-A1 | PROTEIN KINASE INHIBITORS | ORIBASE PHARMA (FR) | 2016-01-14 | — | — | US | disclosed |
| EP-2938612-A1 | PROTEIN KINASE INHIBITORS | OriBase Pharma (FR) | 2015-11-04 | — | — | EP | disclosed |
| US-20140378516-A1 | COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT | UNIVERSITY OF SOUTH FLORIDA | 2014-12-25 | — | — | US | disclosed |
| EP-2800568-A1 | COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT | University Of South Florida (US) | 2014-11-12 | — | — | EP | disclosed |
| WO-2014102376-A1 | PROTEIN KINASE INHIBITORS | ORIBASE PHARMA (FR) | 2014-07-03 | — | — | WO | disclosed |
| WO-2013103760-A1 | COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT | UNIVERSITY OF SOUTH FLORIDA (US) | 2013-07-11 | — | — | WO | disclosed |
| US-7312181-B2 | Acylated thiosemicarbazides as herbicides | CROPSOLUTION, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| WO-2006110276-A2 | ACYLATED THIOSEMICARBAZIDES AS HERBICIDES | CROPSOLUTION, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| US-20060229206-A1 | Acylated thiosemicarbazides as herbicides | ATP CAPITAL LP | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378516-A1 | COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT | LIPA, LCT, GAA | MAPT 2458/4885MEN1 2896/4885KMT2A 1425/4885 |
| US-20160009709-A1 | PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K2 | MAPT 1382/4885MEN1 1780/4885KMT2A 1449/4885 |
| US-10604493-B2 | Compositions, methods of use, and methods of treatment | LIPA, LCT, GAA | MAPT 2458/4885MEN1 2896/4885KMT2A 1425/4885 |
| US-20170088524-A1 | Compositions, Methods of Use, And Methods of Treatment | LIPA, LCT, GAA | MAPT 2458/4885MEN1 2896/4885KMT2A 1425/4885 |
| US-20060229206-A1 | Acylated thiosemicarbazides as herbicides | NAT1, AADAC, HACL2 | MAPT 4149/4885MEN1 4592/4885KMT2A 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.